Guangdong Biolight Meditech has announced that it will acquire a 20% stake in a minimally-invasive medical device company based in Changzhou.
The acquisition is expected to cost CNY20m ($3.04m).
Kunming Longjin Pharmaceutical, manufacturer of natural botanical and chemical freeze-dried medicines based in China, has agreed to sell its pharmaceutical technology development subsidiary based in Beijing for CNY2m ($0.3m).
Royal Philips has completed the acquisition of PathXL from Queen’s University.
By acquiring PathXL, a digital pathology workflow solutions provider, Royal Philips will be able to expand its digital pathology solutions portfolio.
Paramit Corporation has completed the acquisition of Lathrop Engineering, whose design centre in San Jose, California, will be handed over to the former following the transaction.
The acquisition allows Paramit to further improve its design and manufacturing capabilities of complex medical and life sciences instruments.